Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0C5FQ
|
|||
| Former ID |
DNCL003306
|
|||
| Drug Name |
BHT-3009
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Multiple sclerosis [ICD-11: 8A40; ICD-9: 340] | Phase 2 | [1] | |
| Company |
Bayhill Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Myelin basic protein (MBP) | Target Info | . | [2] |
| WikiPathways | MAPK Cascade | |||
| Structural Pathway of Interleukin 1 (IL-1) | ||||
| Spinal Cord Injury | ||||
| Glial Cell Differentiation | ||||
| Neural Crest Differentiation | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00382629) BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis. U.S. National Institutes of Health. | |||
| REF 2 | BHT-3009, a myelin basic protein-encoding plasmid for the treatment of multiple sclerosis. Curr Opin Mol Ther. 2009 Aug;11(4):463-70. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.